Tag Archives: mirvetuximab soravtansine

June, 2018

February, 2016

  • 5 February

    ImmunoGen and Merck Partner for Ovarian Cancer Combination Therapy Study

    WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have entered into a clinical research collaboration for the assessment of ImmunoGen’s mirvetuximab soravtansine in combination with …